223 related articles for article (PubMed ID: 1724398)
1. Current concepts in the treatment of genitourinary tract disorders in the older individual.
Atala A; Amin M
Drugs Aging; 1991 May; 1(3):176-93. PubMed ID: 1724398
[TBL] [Abstract][Full Text] [Related]
2. A modern rationale for the use of phenoxybenzamine in urinary tract disorders and other conditions.
Te AE
Clin Ther; 2002 Jun; 24(6):851-61; discussion 837. PubMed ID: 12117078
[TBL] [Abstract][Full Text] [Related]
3. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders.
Chrisp P; Sorkin EM
Drugs Aging; 1991; 1(6):487-509. PubMed ID: 1794035
[TBL] [Abstract][Full Text] [Related]
4. [Drugs for the treatment of benign prostatic hypertrophy].
Caprino L
Minerva Urol Nefrol; 2000 Jun; 52(2):87-92. PubMed ID: 11085067
[TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
[TBL] [Abstract][Full Text] [Related]
6. A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat.
Oudot A; Oger S; Behr-Roussel D; Caisey S; Bernabé J; Alexandre L; Giuliano F
BJU Int; 2012 Nov; 110(9):1352-8. PubMed ID: 22448674
[TBL] [Abstract][Full Text] [Related]
7. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
8. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
9. Impact of phytotherapy on utility scores for 5 benign prostatic hyperplasia/lower urinary tract symptoms health states.
Dedhia RC; Calhoun E; McVary KT
J Urol; 2008 Jan; 179(1):220-5. PubMed ID: 18001791
[TBL] [Abstract][Full Text] [Related]
10. Medical management of prostatic diseases.
Schlegel PN
Adv Intern Med; 1994; 39():569-601. PubMed ID: 7511322
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
[TBL] [Abstract][Full Text] [Related]
12. Lower urinary tract symptoms, benign prostatic hyperplasia/benign prostatic enlargement and erectile dysfunction: are these conditions related to vascular dysfunction?
Shimizu S; Tsounapi P; Shimizu T; Honda M; Inoue K; Dimitriadis F; Saito M
Int J Urol; 2014 Sep; 21(9):856-64. PubMed ID: 24930630
[TBL] [Abstract][Full Text] [Related]
13. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.
Wilde MI; Fitton A; McTavish D
Drugs; 1993 Mar; 45(3):410-29. PubMed ID: 7682910
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology for common urologic diseases: 2011 review for the primary care physician.
Liu XS; Folia C; Gomella LG
Can J Urol; 2011 Apr; 18 Suppl():24-38. PubMed ID: 21501548
[TBL] [Abstract][Full Text] [Related]
15. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies.
Brock GB; McVary KT; Roehrborn CG; Watts S; Ni X; Viktrup L; Wong DG; Donatucci C
J Urol; 2014 Feb; 191(2):405-11. PubMed ID: 24096120
[TBL] [Abstract][Full Text] [Related]
16. Benign prostatic hyperplasia. Current pharmacological treatment.
Jønler M; Riehmann M; Bruskewitz RC
Drugs; 1994 Jan; 47(1):66-81. PubMed ID: 7510622
[TBL] [Abstract][Full Text] [Related]
17. Benign prostatic hyperplasia - progress in pathophysiology and management.
Dobrek Ł; Thor PJ
Pol Merkur Lekarski; 2015 Nov; 39(233):263-70. PubMed ID: 26637089
[TBL] [Abstract][Full Text] [Related]
18. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone.
Engel JB; Schally AV
Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):157-67. PubMed ID: 17237842
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.
Casabé A; Roehrborn CG; Da Pozzo LF; Zepeda S; Henderson RJ; Sorsaburu S; Henneges C; Wong DG; Viktrup L
J Urol; 2014 Mar; 191(3):727-33. PubMed ID: 24096118
[TBL] [Abstract][Full Text] [Related]
20. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
Gormley GJ; Stoner E; Bruskewitz RC; Imperato-McGinley J; Walsh PC; McConnell JD; Andriole GL; Geller J; Bracken BR; Tenover JS
N Engl J Med; 1992 Oct; 327(17):1185-91. PubMed ID: 1383816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
